Eye Images Collected to Help Build a Screening Tool for Macular Degeneration
Collects eye images from people aged 50 and older, with or without macular degeneration.
Plain-language title generated from the registry record
Registry title: Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
Key facts
- Where
- Adelaide, AustraliaSee the site
Where in Australia
- Adelaide Eye and Retina CentreAdelaide, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Wisconsin, Madison
- Trial code
- NCT06924021
- Record updated
- 30 October 2026
- Original description
1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.Read full original descriptionShow less
Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.
Inclusion: Participants greater than or equal to 50 years of age at time of signing Informed Consent Form; Willing to comply with all study procedures and sign the Informed Consent Form (ICF); Individuals with normal healthy eyes or diagnosed with any stage of Age-Related Macular Degeneration (treatment naïve patients with early, intermediate, or late AMD). The diagnosis and eligibility review will be confirmed by Central Reading Center.
Exclusion: Severe vision loss requiring urgent surgery; Currently or previously enrolled in an interventional AMD clinical trial; Contraindicated for acquiring retinal images due to narrow anterior chamber angles or hypersensitivity to light; A systemic or ocular condition that in the opinion of the Investigator would preclude participation in the study; Therapeutic treatment for any type of AMD, in either eye. Supplements, such as AREDS2 formula, are allowed; Unable to acquire adequate quality images, as evaluated by the Central Reading Center; Unwilling to sign informed consent form.